Skip to main content
Zura Bio Ltd logo

Zura Bio Ltd — Investor Relations & Filings

Ticker · ZURA ISIN · KYG507521071 LEI · 549300LQXD6M2MIQFN24 US Manufacturing
Open in API
Filings indexed 394 across all filing types
Latest filing 2023-03-14 Regulatory Filings
Country KY Cayman Islands
Listing US ZURA

About Zura Bio Ltd

https://zurabio.com/

Zura Bio Ltd. is a multi-asset, clinical-stage biotechnology company focused on developing novel medicines for severe autoimmune and inflammatory disorders. The company's strategy centers on dual-pathway biology, aiming to create transformative solutions for patients whose needs are not adequately met by single-pathway medicines. Its development portfolio includes the therapeutic candidates tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880). Zura Bio's mission is to enhance patient well-being by developing innovative dual-pathway antibody therapies that demonstrate efficacy, safety, and dosing convenience for challenging immunological conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content includes announcements about a voluntary transfer of listing from NYSE to Nasdaq, a subscription agreement for shares related to a business combination, and forward-looking statements about the business combination with Zura Bio Limited. There are no detailed financial statements or comprehensive financial analysis present, only disclosures about corporate events and transactions. The document also includes a press release as an exhibit. This type of filing is typically categorized as a Regulatory Filing (RNS) because it is a current report disclosing material corporate events but not a full financial report or earnings release. The document length (12,983 characters) is substantial, but the content is focused on event disclosure rather than financial results or management discussion. Therefore, the best classification is Regulatory Filings (RNS).
2023-03-14 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by JATT Acquisition Corp dated March 9, 2023. It reports an amendment to a Forward Purchase Agreement related to a business combination with Zura Bio Limited. The document includes details about the amendment, share purchases, and ownership changes expected upon closing the business combination. It also contains forward-looking statements and references to other SEC filings such as Form 10-K, 10-Q, and S-4. The document is a current report disclosing material definitive agreements and other events, typical of an 8-K filing. It is not a full annual or quarterly report, audit report, earnings release, or proxy statement. It is a regulatory announcement of material events and agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (13,407 characters) and content confirm it is not a brief announcement or a full financial report but a regulatory filing reporting material events.
2023-03-10 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by JATT Acquisition Corp, dated March 9, 2023. It reports an amendment to a Forward Purchase Agreement related to a business combination with Zura Bio Limited. The document includes details about the amendment, share purchases, and ownership changes expected upon closing the business combination. It also contains forward-looking statements and references to exhibits attached to the filing. The Form 8-K is a current report used to announce material events or agreements but does not contain comprehensive financial statements or detailed financial analysis. It is not an annual or quarterly report, nor a proxy statement or earnings release. The content focuses on a material definitive agreement and other events, which aligns with the purpose of a current report (8-K) filing. Given the nature of the document and its content, the best fitting category is Regulatory Filings (RNS), which serves as a general category for miscellaneous SEC filings that do not fit other specific categories.
2023-03-09 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by JATT Acquisition Corp. It announces the effectiveness of a registration statement on Form S-4 related to a business combination with Zura Bio Limited, the date of an extraordinary general meeting for shareholder approval, and the record date for voting eligibility. It includes a press release as an exhibit and contains forward-looking statements and disclaimers. The document does not contain detailed financial statements or substantive financial data but serves as a current report disclosing material events and updates related to the business combination process. This type of filing is a regulatory announcement of significant corporate events rather than a full financial report or proxy solicitation document. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2023-03-02 English
Regulatory Filings 2023
Regulatory Filings
2023-03-02 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by JATT Acquisition Corp. It announces the effectiveness of a registration statement on Form S-4 related to a business combination with Zura Bio Limited, the date of an extraordinary general meeting for shareholder approval, and the record date for shareholders eligible to vote. The document includes a press release as an exhibit and contains forward-looking statements and disclaimers typical of a current report. There are no detailed financial statements or substantive financial data presented; rather, it is an announcement of events and filings related to the business combination and proxy solicitation. The document is not a full annual or quarterly report, audit report, earnings release, or proxy statement itself, but a current report announcing these matters. Therefore, the appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories.
2023-03-02 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.